Free Trial

Research Analysts Set Expectations for DAWN Q3 Earnings

Day One Biopharmaceuticals logo with Medical background

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at Capital One Financial boosted their Q3 2024 earnings estimates for shares of Day One Biopharmaceuticals in a report released on Wednesday, October 16th. Capital One Financial analyst N. Quibria now forecasts that the company will post earnings of ($0.71) per share for the quarter, up from their previous forecast of ($0.79). The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($1.68) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals' Q4 2024 earnings at ($0.73) EPS and FY2024 earnings at ($2.21) EPS.

A number of other research firms have also recently issued reports on DAWN. Bank of America upgraded shares of Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and raised their target price for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Needham & Company LLC increased their target price on Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, October 9th. Piper Sandler reissued an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $35.71.

View Our Latest Analysis on Day One Biopharmaceuticals

Day One Biopharmaceuticals Price Performance

Day One Biopharmaceuticals stock traded down $0.08 during mid-day trading on Monday, hitting $14.93. 541,855 shares of the company's stock traded hands, compared to its average volume of 920,466. The firm has a 50 day simple moving average of $14.08 and a two-hundred day simple moving average of $14.37. Day One Biopharmaceuticals has a fifty-two week low of $9.76 and a fifty-two week high of $18.07. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -5.95 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million.

Insider Buying and Selling

In related news, General Counsel Adam Dubow sold 3,202 shares of the firm's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the sale, the insider now owns 1,097,535 shares of the company's stock, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,748 shares of company stock valued at $689,072 over the last 90 days. 8.40% of the stock is owned by corporate insiders.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC acquired a new position in Day One Biopharmaceuticals during the third quarter worth about $2,566,000. Handelsbanken Fonder AB lifted its stake in Day One Biopharmaceuticals by 16.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company's stock valued at $376,000 after purchasing an additional 3,900 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $124,000. Point72 Asset Management L.P. bought a new stake in shares of Day One Biopharmaceuticals during the second quarter worth $6,480,000. Finally, Deerfield Management Company L.P. Series C grew its stake in shares of Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company's stock worth $40,281,000 after buying an additional 1,157,825 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Further Reading

Earnings History and Estimates for Day One Biopharmaceuticals (NASDAQ:DAWN)

→ 625,000% Gain (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Day One Biopharmaceuticals right now?

Before you consider Day One Biopharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.

While Day One Biopharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines